Pipeline
We develop in parallel subcutaneous, oral, and transdermal delivery systems.
With multiple delivery methods in development, Starton can expand the number of medicines it is able to deliver continuously, based on patients’ individualized needs and provide multiple avenues for success.
Product Active Indication Preclinical Phase 1 Phase 1b Phase 2 Phase 3
STAR-LLD-SCsubcutaneous infusion
Lenalidomide
Standard Risk Relapsed Refractory Multiple Myeloma (RRMM)
STAR-LLD-OCRoral controlled release
Lenalidomide
Chronic lymphocytic leukemia (CLL)
STAR-LLD-OCRoral controlled release
Lenalidomide
High Risk Relapsed Refractory Multiple Myeloma (RRMM)
STAR-LLD-SCsubcutaneous infusion
Lenalidomide
Combination with CAR T cell therapies
* other active ingredients are being researched at our facility that have not yet been disclosed
STAR-LLD broadly refers to our continuous low-dose formulation of lenalidomide.
SC means subcutaneous delivery. SC has broader applicability with multiple ambulatory pumps registered and available in the market and a growing number of on-body injectors. For this reason, Starton began the development of STAR-LLD using an ambulatory pump. This allowed us to get into the clinic sooner.
OCR means oral controlled release.